Loading organizations...
Loading organizations...
Novamab is a technology company.
Novamab has raised $38.0M across 2 funding rounds.
Novamab has raised $38.0M in total across 2 funding rounds.
Novamab is a Shanghai-based biopharmaceutical company focused on developing innovative VHH antibody drugs targeting respiratory and inflammatory diseases. The company aims to provide safer and more effective treatment options for patients.
Novamab is a clinical-stage biotechnology company specializing in the research and development of innovative VHH (single-domain) antibody drugs, primarily targeting respiratory diseases, autoimmune disorders, and oncology. It develops highly differentiated nanobody-based therapeutics, including inhaled, oral, and multi-specific antibody platforms, aiming to improve drug efficacy and patient compliance. Novamab serves patients with conditions such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), with several products advancing through clinical trials, demonstrating strong growth momentum in the biopharma sector[1][2][4][6].
Founded in 2017 in Shanghai International Medical Park, Novamab was established by Dr. Yakun Wan, a leading expert with over 17 years of VHH antibody research experience. The idea emerged from Dr. Wan’s extensive academic and postdoctoral work in antibody drug development, leading to China’s first VHH antibody R&D team in drug development. Early milestones include building proprietary technology platforms and securing recognition as a high-tech enterprise in Shanghai in 2020, which catalyzed further innovation and investment[1][2][3].
Novamab rides the growing trend of nanobody therapeutics, which offer advantages over traditional antibodies such as smaller size, better tissue penetration, and novel delivery routes (inhalation, oral). The timing is favorable due to increasing demand for targeted biologics in respiratory and inflammatory diseases, coupled with advances in bioprocessing technologies. Novamab’s innovation strengthens China’s biopharma ecosystem by filling critical gaps in nanobody drug development and manufacturing, fostering domestic capabilities in a globally competitive field[1][2][3][4].
Looking ahead, Novamab is poised to expand its clinical pipeline and commercial footprint, particularly in respiratory and autoimmune indications. Trends such as personalized medicine, biologics delivery innovation, and growing global demand for novel therapies will shape its trajectory. Its continued investment in R&D and strategic partnerships will likely enhance its influence as a leader in VHH antibody therapeutics, potentially setting new standards for nanobody drug development in China and worldwide[1][2][4].
Novamab has raised $38.0M in total across 2 funding rounds.
Novamab's investors include Qiming Venture Partners, Chengdu Biocity Fund.
Novamab has raised $38.0M across 2 funding rounds. Most recently, it raised $24.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $24.0M Series B | Qiming Venture Partners | |
| Dec 21, 2023 | $14.0M Series B | Chengdu Biocity Fund |